Patent 7279159 was granted and assigned to Regeneron Pharmaceuticals, Inc. on October, 2007 by the United States Patent and Trademark Office.
Nucleic acid molecules and multimeric proteins capable of binding vascular endothelial growth factor (VEGF). VEGF traps are disclosed which are therapeutically useful for treating VEGF-associated conditions and diseases, and are specifically designed for local administration to specific organs, tissues, and/or cells.